The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement
Open accessAbstract
BACKGROUND: Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known. METHODS: In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a mean (±SD) of 90±15 days after randomization. The primary end point was the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed. RESULTS: A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 to -1.9; P = 0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5). In the main trial, the risk of death or thromboembolic events and the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively). CONCLUSIONS: In a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy was more effective than an antiplatelet-based strategy in preventing subclinical leaflet-motion abnormalities. However, in the main trial, the rivaroxaban-based strategy was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than the antiplatelet-based strategy. (Funded by Bayer; GALILEO-4D ClinicalTrials.gov number, NCT02833948.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Smith, C. R., Leon, M. B., Mack, M. J., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103510 · Cited by 6,345
Self-citation2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Self-citationTranscatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Leon, M. B., Smith, C. R., Mack, M. J., Makkar, R. R., Svensson, L. G., Kodali, S. K., Thourani, V. H., Tuzcu, E. M., Miller, D. C., Herrmann, H. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514616 · Cited by 5,053
Self-citationTranscatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Mack, M. J., Leon, M. B., Thourani, V. H., Makkar, R., Kodali, S. K., Russo, M., Kapadia, S. R., Malaisrie, S. C., Cohen, D. J., Pibarot, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814052 · Cited by 4,847
Self-citationTranscatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
Popma, J. J., Deeb, G. M., Yakubov, S. J., Mumtaz, M., Gada, H., O’Hair, D., Bajwa, T., Heiser, J. C., Merhi, W., Kleiman, N. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816885 · Cited by 3,674
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Reardon, M. J., Van Mieghem, N. M., Popma, J. J., Kleiman, N. S., Søndergaard, L., Mumtaz, M., Adams, D. H., Deeb, G. M., Maini, B., Gada, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700456 · Cited by 3,009
Self-citationTranscatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis
Adams, D. H., Popma, J. J., Reardon, M. J., Yakubov, S. J., Coselli, J. S., Deeb, G. M., Gleason, T. G., Buchbinder, M., Hermiller, J., Kleiman, N. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400590 · Cited by 2,902
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves
Makkar, R. R., Fontana, G., Jilaihawi, H., Chakravarty, T., Kofoed, K. F., De Backer, O., Asch, F. M., Ruiz, C. E., Olsen, N. T., Trento, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509233 · Cited by 1,051
Self-citation2014 AHA/ACC guideline for the management of patients with valvular heart disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.05.014 · Cited by 989
Cited by
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Généreux, P., Piazza, N., Alu, M. C., Nazif, T., Hahn, R. T., Pibarot, P., Bax, J. J., Leipsic, J. A., Blanke, P., Blackstone, E. H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.038 · Cited by 1,313
Self-citation2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., Ajmone Marsan, N., Barili, F., Bonaros, N., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,072
Self-citationVARC-3 WRITING COMMITTEE, Généreux, P., Piazza, N., Alu, M. C., Nazif, T., Hahn, R. T., Pibarot, P., Bax, J. J., Leipsic, J. A., Blanke, P., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa799 · Cited by 915
Self-citation
Metadata
- Authors
- De Backer, O., Dangas, G. D., Jilaihawi, H., Leipsic, J. A., Terkelsen, C. J., Makkar, R., Kini, A. S., Veien, K. T., Abdel-Wahab, M., Kim, W.-K., Balan, P., Van Mieghem, N., Mathiassen, O. N., Jeger, R. V., Arnold, M., Mehran, R., Guimarães, A. H. C., Nørgaard, B. L., Kofoed, K. F., Blanke, P., Windecker, S., & Søndergaard, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-09
- Volume
- 382
- Issue
- 2
- Pages
- 130-139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2982829887
- Cited by
- 293
- References
- 27
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. https://app.cochat.ai/papers/10.1056/nejmoa1911426
- The paper
- De Backer, O., Dangas, G. D., Jilaihawi, H., Leipsic, J. A., Terkelsen, C. J., Makkar, R., Kini, A. S., Veien, K. T., Abdel-Wahab, M., Kim, W.-K., Balan, P., Van Mieghem, N., Mathiassen, O. N., Jeger, R. V., Arnold, M., Mehran, R., Guimarães, A. H. C., Nørgaard, B. L., Kofoed, K. F., . . . Søndergaard, L. (2020). Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1911426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.